Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials.
Munveer ThindHarry J CrijnsGerald V NaccarelliJames A ReiffelValérie Corp Dit GentiMattias WielochAndrew KorenPeter R KoweyPublished in: Journal of cardiovascular electrophysiology (2020)
Patients requiring baseline cardioversion represent a distinct population, having more underlying cardiovascular disease and experiencing a shorter time to AF/AFL recurrences. Dronedarone was associated with improved efficacy vs placebo regardless of cardioversion status.